Next >

25th September 2026

Curium expands long-standing collaboration with the University of Missouri Research Reactor to strengthen the U.S. supply chain for a critical cancer isotope

  • Curium has signed a new multi-year Irradiation Services agreement with the University of Missouri Research Reactor (MURR) to support the production of lutetium-177 (Lu-177), a critical isotope used in targeted cancer therapies
  • The agreement secures U.S.-based irradiation capacity for Curium’s Lu-177 supply chain as demand for radiopharmaceutical therapies continues to grow

(Boston, MA – 25th September, 2026) – Curium™, a global leader in nuclear medicine, has signed a new multi-year Irradiation Services agreement with the University of Missouri Research Reactor (MURR), expanding a long-standing collaboration to support the production of lutetium-177 (Lu-177). Lu-177 is a critical medical isotope increasingly used in precision therapies to target and destroy cancer cells.

Under the agreement, MURR will provide irradiation services in support of Curium’s clinical trials and next-generation radiopharmaceuticals. As demand for targeted radiopharmaceutical therapies continues to grow, the agreement reinforces a shared commitment to advancing public health, fostering innovation, and building U.S. infrastructure for critical medical technologies.

Matt Sanford, Executive Director of MURR, said: “This agreement builds on a long-standing, mutually beneficial collaboration between MURR and Curium to meet the growing demand for medical isotopes.Our reactor’s capabilities and unique operating schedule position us to support the expanding global need for radioisotopes, including Lu-177.”

Curium is a leading global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that transform the way cancer is diagnosed and treated. Headquartered in Boston with offices around the world, Curium’s mission is to find new and better ways to serve more than 14 million patients annually.

Michael Patterson, CEO Curium North America, said: “We are proud to continue our partnership with the University of Missouri Research Reactor on this important initiative. MURR has been an exceptionally reliable partner in our isotope supply chain, and this extended collaboration will help ensure patients receive the treatments they need.”

MURR is the nation’s highest-powered university research reactor and a leading producer of medical isotopes. Operating every day of the year, the facility provides radioisotopes for researchers, health care providers and radiopharmaceutical companies worldwide.

Mun Choi, President of the University of Missouri, said: “Mizzou and Curium have a strong partnership focused on advancing nuclear medicine to save and improve lives in Missouri and around the world. Lutetium-177 is a game-changing innovation in the fight against cancer, and this collaboration builds on our shared success and the immense capabilities of MURR, the most powerful reactor of its kind in the country.”

Todd Graves, Chair of the University of Missouri Board of Curators, said:

“Our continued partnership with Curium solidifies MURR’s crucial role as a leading producer of medical isotopes in the U.S. Mizzou and MURR tackle global health challenges while expanding economic and workforce opportunities in Missouri and creating life-saving solutions for all.”